Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy
Science Advances · 13.09.2024 · 10 (37)
DOI: 10.1126/sciadv.adi7764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 13.09.2024. Verfasst von Yun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shan…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Syndecan-1. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Tumor cell–originated events prevent efficient antitumor immune response and limit the application of anti-PD1 checkpoint immunotherapy. We show that syndecan-1 (SDC1) has a critical role in the regulation of T cell–mediated control of tumor growth. SDC1 inhibition increases the permeation of CD8 + T cells into tumors and triggers CD8 + T cell–mediated control of tumor growth, accompanied by increased proportions of progenitor-exhausted and effector-like CD8 + T cells. SDC1 deficiency alters multiple signaling events in tumor cells, including enhanced IFN-γ–STAT1 signaling, and augments antigen presentation and sensitivity to T cell–mediated cytotoxicity. Combinatory inhibition of SDC1 markedly potentiates the therapeutic effects of anti-PD1 in inhibiting tumor growth. Consistently, the findings are supported by the data from human tumors showing that SDC1 expression negatively correlates with T cell presence in tumor tissues and the response to immune checkpoint blockade therapy. Our findings suggest that SDC1 inhibits antitumor immunity, and that targeting SDC1 may promote anti-PD1 response for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.
- Affiliated Cancer Hospital and Institute, Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Yun Liu, Chen Xu, Li Zhang, Zhaojuan Yang, Kun Jiao, Yongzhong Liu
Zitieren
APA
Liu, Y., Xu, C., Zhang, L., Xu, G., Yang, Z., Xiang, L., Jiao, K., Chen, Z., Zhang, X., & Liu, Y. (2024). Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy. Science Advances, 10(37). https://doi.org/10.1126/sciadv.adi7764
Vancouver
Liu Y, Xu C, Zhang L, Xu G, Yang Z, Xiang L, et al. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy. Science Advances. 2024;10(37). doi:10.1126/sciadv.adi7764
BibTeX
@article{Liu2024,
author = {Liu, Yun and Xu, Chen and Zhang, Li and Xu, Guiqin and Yang, Zhaojuan and Xiang, Lvzhu and Jiao, Kun and Chen, Zehong and Zhang, Xiaoren and Liu, Yongzhong},
title = {Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {37},
doi = {10.1126/sciadv.adi7764}
}
EUVIMED